Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis (NCT07695701) | Clinical Trial Compass
RecruitingPhase 4
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
United States150 participantsStarted 2026-07
Plain-language summary
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Key Inclusion Criteria:
* Participants aged 18 to 80
* Confirmed diagnosis of ATTR-CM requiring targeted therapy
* At screening: New York Heart Association (NYHA) Class I/II; estimated glomerular filtration rate (eGFR) ≥40 mL/min/1.73m2; left ventricular ejection fraction (LVEF) \>35%; left ventricular (LV) wall thickness ≥12 mm.
* Heart failure condition has been clinically stable for at least 6 weeks prior to screening.
Key Exclusion Criteria:
* Current or planned implantation of a cardiac implantable electronic device (eg, pacemaker, implantable cardiac defibrillator).
* Acute myocardial infarction, acute coronary syndrome or coronary revascularization, or experienced stroke or transient ischemic attack within 90 days prior to screening.
* Hemodynamic instability.
* Likely to undergo heart transplantation within 12 months from screening.
* Confirmed diagnosis of AL amyloidosis at screening.
* At screening: NYHA Class III/IV; National Amyloidosis Center (NAC) Stage 3.
* Prior or current treatment with acoramidis.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is a Phase 4 trial studying acoramidis in ATTR-CM patients, does that mean acoramidis is already approved, and if so, how does participating in this study differ from simply being prescribed it as a standard treatment?
2This trial is measuring cardiac function improvement using cardiac MRI — am I a good candidate for cardiac MRI, and are there any reasons like a pacemaker or kidney issues that might make that imaging test difficult or risky for me?
3The trial is actively recruiting right now — what would my actual commitment look like in terms of clinic visits, imaging appointments, and follow-up, and is that realistic given my current health and daily life?
4Since the primary goal is to measure how acoramidis affects heart function in ATTR-CM using CMR imaging, what would we learn from my participation that we might not learn just from my regular echocardiograms, and does that benefit me directly or mainly future patients?
5Given my specific type of ATTR-CM — whether it's hereditary or wild-type — is this trial designed to include patients like me, and is there a standard treatment path we should consider first before enrolling in a study?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
To assess the effect of acoramidis on cardiac function improvement by CMR in participants with ATTR-CM.